Short answer
Olema Pharmaceuticals, Inc. (OLMA) filed its Q1 2026 10-Q quarterly report on May 12, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$53M
- −74.7% YoY
- EPS (diluted)
- −$0.52
- −44.4% YoY
Source: XBRL data from the Olema Pharmaceuticals, Inc. (OLMA) Q1 2026 10-Q on SEC EDGAR. USD.
Olema Pharmaceuticals, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged from $0 YoY; no product sales
- Net loss $53.1M vs $30.4M YoY; operating expenses $58.0M vs $34.9M
- R&D $49.2M vs $30.6M, driven by clinical development and personnel costs
- Cash, equivalents and marketable securities $505.3M; accumulated deficit $650.6M
- OPERA-01 top-line results expected fall 2026; potential NDA filing in 2027
Risk Factors
- No newly added risk factors identifiable; provided section contains standard clinical-stage biopharmaceutical risks
- Capital requirement: existing cash, cash equivalents and marketable securities insufficient to complete palazestrant and OP-3136 development
- Regulatory risk: no pivotal trial completed and no NDA submitted to FDA
- Operational risk: third-party CRO or investigator failures could delay trials or prevent regulatory approval
- Financial risk: $3.0 million outstanding under Credit Facility with maturity extended to January 1, 2029
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Olema Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.